UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000057176
Receipt number R000065343
Scientific Title Thrombus aspiration in acute coronary syndrome: Pathology and OCT Correlations
Date of disclosure of the study information 2025/02/28
Last modified on 2025/02/28 16:47:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Thrombus aspiration in acute coronary syndrome: Pathology and OCT Correlations

Acronym

TAPOS

Scientific Title

Thrombus aspiration in acute coronary syndrome: Pathology and OCT Correlations

Scientific Title:Acronym

TAPOS

Region

Japan Europe


Condition

Condition

Acute Coronary Syndrome (ACS)

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

OCT has clinically contributed to disclose the mechansm of acute coronary syndrome (ACS) including ruptured fibrous (RFC-ACS), plaque erosion (i.e. intact fibrous caps: IFC-ACS) or calcified nodule (CN-ACS). However, it has not yet been fully examined whether OCT findings coincide with in-vivo pathological analysis in ACS. To disclose the mechanism of ACS and role of macrophage phenotype, the investigators prosepectively performed OCT imaging and athero-thrombotic aspiration before PCI.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary endpoint is a composite of cardiovascular death, acute coronary syndrome (ACS), ischemia-driven revascularization, cardiogenic shock, and cardiac failure required hospital admission for 3 years.

Key secondary outcomes

Secondary endpoints are the individual components of the primary endpoints.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Aged >20 years, (2) a diagnosis of ACS, (3) native coronary artery lesions, (4) optical coherence tomography with sufficient quality before PCI, (5) successful thrombus aspiration with enough amount of thrombus. Recent guidelines and consensus documents indicated that routine thrombus aspiration is not recommended, but in cases of large residual thrombus burden, thrombus aspiration may be considered. Therefore, we performed athero-thrombotic aspiration only in patients who would have a merit of the aspiration procedure due to large thrombus burden.

Key exclusion criteria

(1) they have cardiogenic shock, (2) they have coronary bypass grafting (CABG), (3) they have contraindications to anticoagulation and anti-platelet therapy, (4) lesions located in tortuous vessels, in ostial segment, and in the left main stem are excluded from the study due to the difficulty in performing high-quality intracoronary imaging.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name YUKIO
Middle name
Last name OZAKI

Organization

Fujita Health University School of Medicine

Division name

Cardiology

Zip code

461-0021

Address

1-98 Dengaku, Kutsukake, Toyoake, Japan 470-1192

TEL

08030713131

Email

yukio.ozaki7@gmail.com


Public contact

Name of contact person

1st name YUKIO
Middle name
Last name OZAKI

Organization

Fujita Health University School of Medicine

Division name

Cardiology

Zip code

470-1192

Address

1-98 Dengaku, Kutsukake, Toyoake, Japan 470-1192

TEL

+819015609030

Homepage URL


Email

yukio.ozaki7@gmail.com


Sponsor or person

Institute

Other

Institute

Department

Personal name

YUKIO OZAKI


Funding Source

Organization

Other

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Fujita Health University School of Medicine

Address

1-98 Dengaku, Kutsukake, Toyoake, Japan 470-1192

Tel

08030713131

Email

yukio.ozaki7@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 02 Month 28 Day


Related information

URL releasing protocol

Not yet

Publication of results

Unpublished


Result

URL related to results and publications

Not yet

Number of participants that the trial has enrolled

200

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results

2028 Year 12 Month 31 Day

Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2016 Year 01 Month 01 Day

Date of IRB

2016 Year 07 Month 25 Day

Anticipated trial start date

2016 Year 07 Month 25 Day

Last follow-up date

2029 Year 12 Month 31 Day

Date of closure to data entry

2030 Year 12 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

Pathological analysis is performed independently without any information of clinical and OCT data at Centre for Inherited Cardiovascular Diseases, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy. The investigators compare OCT imaging analysis results, in-vivo pathological analysis results and clinical outcome without any interaction.


Management information

Registered date

2025 Year 02 Month 28 Day

Last modified on

2025 Year 02 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065343